Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alzheimer's disease
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
gilead sciences
4
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
biogen
biotech
diagnostics
merck
novartis
pfizer
startups
aducanumab
affordable care act
amgen
What
bio
drug
4
×
roundup
4
×
acquisitions
biggest
biogen’s
ceo
nash
news
week
aducanumab
albert
alzheimer’s
amyloid
angst
approval
bagged
billions
biogen
biopharmaceutical
bourla
brammer
build
buy
companies
company
company’s
convo
crispr
daniel
debut
dyne’s
earlier
effects
failure
failures
felt
future
gilead
imports
Language
unknown
unset
Current search:
roundup
×
" gilead sciences "
×
drug
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More